Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 6/20 | 0.68 |
| ▸ | NPY2R | P49146 | 8/20 | 0.67 |
| ▸ | NPY4R | P50391 | 8/20 | 0.67 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.67 |
| ▸ | NPY1R | P25929 | 6/20 | 0.67 |
| ▸ | KDM1A | O60341 | 2/20 | 0.64 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.63 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.63 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | KDM5A | P29375 | 1/20 | 0.62 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29533701 | 1.00 | TFPI (0.68) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29424820 | 1.00 | TFPI (0.68) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29973299 | 0.99 | TFPI (0.66) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30017187 | 0.92 | NPY2R (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31121841 | 0.92 | NMUR2 (0.68) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29625796 | 0.91 | KDM1A (0.66) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30176437 | 0.91 | TFPI (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30176414 | 0.91 | TFPI (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30432104 | 0.91 | TFPI (0.69) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29625797 | 0.91 | TFPI (0.66) | TFPINPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | disclosed |
| EP-3835319-B1 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H LUNDBECK AS (DK) | 2025-11-19 | — | — | EP | disclosed |
| EP-3315968-B1 | UNIVERSAL ANTIGEN RETRIEVAL COMPOUNDS AND METHODS OF USE | UNIV HOUSTON SYSTEM (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12428475-B2 | Humanized anti-ACTH antibodies and use thereof | H. LUNDBECK A/S (DK) | 2025-09-30 | — | — | US | disclosed |
| US-12351627-B2 | Anti-ACTH antibodies and use thereof | H. LUNDBECK A/S (DK) | 2025-07-08 | — | — | US | disclosed |
| WO-2025085293-A1 | SOLVENT FREE RESORBABLE RESIN FOR 3D PRINTING | DUKE UNIVERSITY (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-119719839-A | Photovoltaic power generation power working condition data generation method based on improved diffusion model | 南方电网新型电力系统(北京)研究院有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-114430857-B | Ion trap mass spectrometer, mass spectrometry method, and computer readable medium storing control program | 株式会社岛津制作所 | 2025-02-25 | — | — | CN | disclosed |
| US-20240309065-A1 | SHORT APOC-II MIMETIC PEPTIDES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240165127-A1 | CONTRAST AGENT FOR DIAGNOSIS OF VASCULAR DISEASE CONTAINING GADOLINIUM-BASED COMPOUND AS ACTIVE INGREDIENT AND SYNTHESIS METHOD THEREFOR | DAEGU CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2024-05-23 | — | — | US | disclosed |
| EP-4359432-A2 | SHORT APOC-II MIMETIC PEPTIDES AND METHODS OF USE | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117580857-A | APOC-II short mimetic peptides and methods of use | 美国政府(由卫生和人类服务部的部长所代表) | 2024-02-20 | — | — | CN | disclosed |
| US-11887833-B2 | Ion trap mass spectrometer, mass spectrometry method and non-transitory computer readable medium storing control program | SHIMADZU CORPORATION (JP) | 2024-01-30 | — | — | US | disclosed |
| US-20230174641-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | H LUNDBECK AS (DK) | 2023-06-08 | — | — | US | disclosed |
| WO-2022271814-A2 | SHORT APOC-II MIMETIC PEPTIDES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220277951-A1 | ION TRAP MASS SPECTROMETER, MASS SPECTROMETRY METHOD AND NON-TRANSITORY COMPUTER READABLE MEDIUM STORING CONTROL PROGRAM | SHIMADZU CORPORATION (JP) | 2022-09-01 | — | — | US | disclosed |
| US-11427631-B2 | Anti-ACTH antibodies and use thereof | H. LUNDBECK A/S (DK) | 2022-08-30 | — | — | US | disclosed |
| CN-114430857-A | Ion trap mass spectrometer, mass spectrometry method, and control program | 株式会社岛津制作所 | 2022-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351627-B2 | Anti-ACTH antibodies and use thereof | CRH, MC2R, GIPR | TFPI 4870/4885NPY2R 250/4885NPY4R 87/4885 |
| US-20230174641-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | CRH, MC2R, GIPR | TFPI 4870/4885NPY2R 250/4885NPY4R 87/4885 |
| US-11427631-B2 | Anti-ACTH antibodies and use thereof | CRH, MC2R, GIPR | TFPI 4870/4885NPY2R 250/4885NPY4R 87/4885 |
| US-20240165127-A1 | CONTRAST AGENT FOR DIAGNOSIS OF VASCULAR DISEASE CONTAINING GADOLINIUM-BASED COMPOUND AS ACTIVE INGREDIENT AND SYNTHESIS METHOD THEREFOR | CTRL, CELA1, PRSS1 | TFPI 254/4885NPY2R 3234/4885NPY4R 2681/4885 |
| US-12428475-B2 | Humanized anti-ACTH antibodies and use thereof | CRH, MC2R, CRHR1 | TFPI 4802/4885NPY2R 275/4885NPY4R 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.